Pfizer has made the “difficult decision” to draw a line under its biosimilar endeavors in China, agreeing to sell its biologics manufacturing site in Hangzhou to local biologics contract development and manufacturing firm WuXi Biologics and halt its biosimilar programs in the country.
The agreement, which is expected to close in the first half of 2021, and new strategic direction followed “a comprehensive...






